LOS ANGELES--(BUSINESS WIRE)--Cougar Biotechnology, Inc. (NASDAQ: CGRB) announced that results from ongoing Phase II clinical trials of Cougar’s investigational drug CB7630 (abiraterone acetate) were presented at the ASCO Genitourinary Cancers Symposium that is currently taking place in Orlando, Florida. The data were presented today in two poster presentations. These presentations are further detailed below:
